Tropical Infectious Diseases Research & Education Centre (TIDREC), Universiti Malaya, Kuala Lumpur 50603, Malaysia.
Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
Int J Mol Sci. 2023 May 31;24(11):9589. doi: 10.3390/ijms24119589.
Despite the fact that coronavirus disease 2019 (COVID-19) treatment and management are now considerably regulated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still one of the leading causes of death in 2022. The availability of COVID-19 vaccines, FDA-approved antivirals, and monoclonal antibodies in low-income countries still poses an issue to be addressed. Natural products, particularly traditional Chinese medicines (TCMs) and medicinal plant extracts (or their active component), have challenged the dominance of drug repurposing and synthetic compound libraries in COVID-19 therapeutics. Their abundant resources and excellent antiviral performance make natural products a relatively cheap and readily available alternative for COVID-19 therapeutics. Here, we deliberately review the anti-SARS-CoV-2 mechanisms of the natural products, their potency (pharmacological profiles), and application strategies for COVID-19 intervention. In light of their advantages, this review is intended to acknowledge the potential of natural products as COVID-19 therapeutic candidates.
尽管 2019 年冠状病毒病（COVID-19）的治疗和管理现在已经得到了相当程度的规范，但严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）仍然是 2022 年的主要死亡原因之一。在低收入国家，COVID-19 疫苗、FDA 批准的抗病毒药物和单克隆抗体的供应仍然是一个需要解决的问题。天然产物，特别是传统中药（TCM）和药用植物提取物（或其有效成分），对药物重定位和合成化合物库在 COVID-19 治疗中的主导地位提出了挑战。它们丰富的资源和出色的抗病毒性能使天然产物成为 COVID-19 治疗的相对廉价且易于获得的替代品。在这里，我们特意回顾了天然产物抗 SARS-CoV-2 的机制、它们的效力（药理学特征）以及在 COVID-19 干预中的应用策略。鉴于它们的优势，本综述旨在承认天然产物作为 COVID-19 治疗候选药物的潜力。
